Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 30

Sort by

Sort Order Select

Journal Articles

Analysis of Red Blood Cells Oxidative Stress Susceptibility in Sickle Cell Disease Variants Using the Roxyscan

Carolina Andrea Hernandez, Richard van Wijk, Marissa J.M. Traets, Wouter W. van Solinge, Eduard J. Van Beers, Minke A.E. Rab, Anita W. Rijneveld

Blood (2024) 144 (Supplement 1): 5273.

https://doi.org/10.1182/blood-2024-204720

Published: 2024

Journal Articles

Oxygen Gradient Ektacytometry Is Associated with Markers of Hemolysis and Inflammation in a Large Sickle Cell Disease Cohort within the GenoMed4ALL Project

Blood (2024) 144 (Supplement 1): 290.

https://doi.org/10.1182/blood-2024-200639

Published: 2024

Journal Articles

WU-CART-007 (WT-7), an Allogeneic CAR T-Cell Targeting CD7 in Relapsed/Refractory (R/R) T-Cell Acute Lymphoblastic Leukemia/Lymphoma (T-ALL/LBL): Phase 2 Results

Blood (2024) 144 (Supplement 1): 3450.

https://doi.org/10.1182/blood-2024-202005

Published: 2024

Journal Articles

Data Driven Research through the European RADeep Registry and the Use of Artificial Intelligence Towards Personalized Medicine in Sickle Cell Disease

Blood (2024) 144 (Supplement 1): 1138.

https://doi.org/10.1182/blood-2024-203331

Published: 2024

Journal Articles

WUC007-03: A Phase 2 Study of Anti-CD7 Allogenic CAR-T Cells (WT-7) in Patients with Relapsed/Refractory (R/R) T-Cell Acute Lymphoblastic Leukemia (T-ALL)/Lymphoblastic Lymphoma (LBL)

Blood (2024) 144 (Supplement 1): 7225.

https://doi.org/10.1182/blood-2024-201825

Published: 2024

Journal Articles

Single-Agent Subcutaneous Blinatumomab for Advanced B-Cell Acute Lymphoblastic Leukemia: Long-Term Follow-up from a Phase 1b Dose Expansion Cohort

Elias Jabbour, Gerhard Zugmaier, Pilar Martinez Sanchez, Jose J. Rifon, Vaibhav Agrawal, Ryan D Cassaday, Thomas Cluzeau, Françoise Huguet, Vladan Vucinic, Boris Böll, Anita W. Rijneveld, Mar Tormo, Maher Abdul-Hay, Paul R Gordon, Alessandro Rambaldi, Hagop M. Kantarjian

Blood (2024) 144 (Supplement 1): 1440.

https://doi.org/10.1182/blood-2024-205662

Published: 2024

Journal Articles

Mapping Total Cortical Volume of Children and Adolescents with Sickle Cell Disease Against Normative Growth Trajectories: First Baseline Results of the Brick Study

Aida Kidane, Marjolein Dremmen, Candace Makeda Moore, Isabelle van der Velpen, Marine Bouyssi-Kobar, Anita W. Rijneveld, Tonya White, Marjon H. Cnossen

Blood (2024) 144 (Supplement 1): 3901.

https://doi.org/10.1182/blood-2024-205469

Published: 2024

Journal Articles

Transcriptional Profiling Directs the Classification of Mixed Phenotype Acute Leukemias into AML, B-ALL or T-ALL

Roger Mulet-Lazaro, Aniko Sijs-Szabó, Remco Hoogenboezem, Stanley Van Herk, Patricia G. Hoogeveen, Francois Kavelaars, Anita Schelen, Willemijn van den Ancker, Arjan A. van de Loosdrecht, Berna Beverloo, Vincent H.J. Van Der Velden, Jan J. Cornelissen, Peter J. M. Valk, Anita W. Rijneveld, Mathijs Arnoud Sanders

Blood (2024) 144 (Supplement 1): 4300.

https://doi.org/10.1182/blood-2024-209773

Published: 2024

Journal Articles

One-Year Safety and Efficacy of Mitapivat in Sickle Cell Disease: Follow-up Results of a Phase 2, Open-Label Study

Myrthe J. van Dijk, Minke A.E. Rab, Brigitte A. van Oirschot, Jennifer Bos, Cleo Derichs, Anita W. Rijneveld, Marjon H. Cnossen, Erfan Nur, Bart J. Biemond, Marije Bartels, Judith J.M. Jans, Wouter W. van Solinge, Roger E.G. Schutgens, Richard van Wijk, Eduard J. Van Beers

Blood (2023) 142 (Supplement 1): 2515.

https://doi.org/10.1182/blood-2023-172829

Published: 2023

Journal Articles

Novel Insights in TKI Resistance in BCR :: ABL1 -Positive B-Cell Acute Lymphoblastic Leukemia Beyond Kinase Domain Mutations

Inge Van Outersterp, Caitlin E.J. Reichert, Aurelie Boeree, Cesca Van De Ven, Brian Kruisinga, Hester A. de Groot-Kruseman, Gabriele Escherich, Anita W. Rijneveld, Judith M. Boer, Monique L. den Boer

Blood (2023) 142 (Supplement 1): 1615.

https://doi.org/10.1182/blood-2023-179704

Published: 2023

Journal Articles

Use of Race and Ethnicity in Sickle Cell Disease Research

Aida Kidane, Minke A.E. Rab, Karlijn Meeks, Amade M'charek, Anita W. Rijneveld

Blood (2023) 142 (Supplement 1): 5317.

https://doi.org/10.1182/blood-2023-179743

Published: 2023

Journal Articles

Pyruvate Kinase Thermostability Is Associated with Red Blood Cell Adhesion, Deformability and Oxygen Affinity in Patients with Sickle Cell Disease

Marissa J.M. Traets, Sigrid van der Veen, Jennifer Bos, Laura van Pelt, Aida Kidane, Brigitte A. van Oirschot, Wouter W. van Solinge, Saskia Schols, Mandy N. Lauw, Marjon H. Cnossen, Erfan Nur, Bart J. Biemond, Eduard J. Van Beers, Anita W. Rijneveld, Richard van Wijk, Minke A.E. Rab

Blood (2023) 142 (Supplement 1): 561.

https://doi.org/10.1182/blood-2023-180755

Published: 2023

Journal Articles

Red Blood Cell Pyruvate Kinase Properties in Sickle Cell Disease - of Mice and Men

Marissa J.M. Traets, Brigitte A. van Oirschot, Titine J.J. Ruiter, Charles Levine, Anita W. Rijneveld, Judith J.M. Jans, Minke A.E. Rab, Yu-Wei Chen, Richard van Wijk

Blood (2023) 142 (Supplement 1): 1115.

https://doi.org/10.1182/blood-2023-173572

Published: 2023

Journal Articles

The HOVON 100 Study in Adult Acute Lymphoblastic Leukemia Re-Analysed By Multi-State Modeling: Benefits and Risks of Clofarabine

Sjoerd J.F. Hermans, Yvette Norden, Jurjen Versluis, Anita W. Rijneveld, Okke De Weerdt, Bart J. Biemond, Arjan A. van de Loosdrecht, Lotte E. Van der Wagen, Mar Bellido, Michel Van Gelder, Walter J.F.M. Van der Velden, Dominik Selleslag, Danielle van Lammeren, Vincent H.J. van der Velden, Liesbeth C. de Wreede, Douwe Postmus, Francesco Pignatti, Jan J. Cornelissen

Blood (2022) 140 (Supplement 1): 8890–8892.

https://doi.org/10.1182/blood-2022-163055

Published: 2022

Journal Articles

Untargeted Metabolomics on Dried Blood Spots of Patients with Sickle Cell Disease Treated with the Pyruvate Kinase Activator Mitapivat

Myrthe J. van Dijk, Sigrid van der Veen, Minke A.E. Rab, Brigitte A. van Oirschot, Jennifer Bos, Cleo Derichs, Anita W. Rijneveld, Marjon H. Cnossen, Erfan Nur, Bart J. Biemond, Marije Bartels, Judith J.M. Jans, Richard van Wijk, Eduard J. van Beers

Blood (2022) 140 (Supplement 1): 21–23.

https://doi.org/10.1182/blood-2022-155997

Published: 2022

Journal Articles

Robust Validation of the UKALL High Hyperdiploid Risk Profile Using Individual Patient Data Collected By the Harmony Alliance

Amir Enshaei, Javier Martinez Martínez Elicegui, Esther Anguiano, Jude Gibson, Mirella Ampatzidou, Michael Doubek, Adele K. Fielding, Edoardo La Sala, Elizabeth Middleton, Anita W. Rijneveld, Amin T. Turki, Ajay Vora, Martin Zimmermann, Anthony V. Moorman

Blood (2022) 140 (Supplement 1): 6369–6370.

https://doi.org/10.1182/blood-2022-157680

Published: 2022

Journal Articles

Safety and Efficacy of Mitapivat (AG-348), an Oral Activator of Pyruvate Kinase R, in Subjects with Sickle Cell Disease: A Phase 2, Open-Label Study (ESTIMATE)

Myrthe J. van Dijk, Minke A.E. Rab, Anita W. Rijneveld, Erfan Nur, Marije Bartels, Judith J.M. Jans, Wouter W. van Solinge, Roger E.G. Schutgens, Richard van Wijk, Eduard J. Van Beers

Blood (2021) 138 (Supplement 1): 2047.

https://doi.org/10.1182/blood-2021-150234

Published: 2021

Journal Articles

Preclinical Development of AT1412, a Patient Derived CD9 Antibody That Does Not Induce Thrombosis for Treatment of B ALL

Blood (2020) 136 (Supplement 1): 41–42.

https://doi.org/10.1182/blood-2020-134088

Published: 2020

Journal Articles

Real-World Effectiveness and Safety of Blinatumomab in Adults with Relapsed or Refractory B-Cell Precursor Acute Lymphoblastic Leukaemia in Europe: 3-Year Results in Philadelphia Chromosome-Negative Patients and a Subset of Patients with Late First Relapse

Xavier Thomas, MD PhD, Anita W Rijneveld, MD PhD, Nicola Fracchiolla, MD, Cyril Šálek, MD, Alexandros Spyridonidis, MD PhD, Sabina Chiaretti, MD PhD, Naufil Alam, PhD, Isabella Pezzani Grueter, PharmD, Abeera Mohammad, MSc, William Kormany, MD, Georg Kreuzbauer, MD, Alessandro Rambaldi, MD

Blood (2020) 136 (Supplement 1): 38–39.

https://doi.org/10.1182/blood-2020-134470

Published: 2020

Journal Articles

AT1412, a Patient-Derived Antibody in Development for the Treatment of CD9 Positive Precursor B-Acute Lymphoblastic Leukemia

Greta De Jong, Sophie E Levie, Remko Schotte, PhD, Wouter Pos, PhD, Daniel Go, Etsuko Yasuda, Madalina Cercel, Susan E van Hal-van Veen, Esmay Frankin, Anikó Szabó, MD, Julien Villaudy, PhD, Pauline M van Helden, PhD, Hans van Eenennaam, PhD, Hergen Spits, PhD, Anita W Rijneveld, MD PhD, Mette D Hazenberg, MD PhD

Blood (2019) 134 (Supplement_1): 4461.

https://doi.org/10.1182/blood-2019-127894

Published: 2019

NARROW

Analysis of Red Blood Cells Oxidative Stress Susceptibility in Sickle Cell Disease Variants Using the Roxyscan

Oxygen Gradient Ektacytometry Is Associated with Markers of Hemolysis and Inflammation in a Large Sickle Cell Disease Cohort within the GenoMed4ALL Project

WU-CART-007 (WT-7), an Allogeneic CAR T-Cell Targeting CD7 in Relapsed/Refractory (R/R) T-Cell Acute Lymphoblastic Leukemia/Lymphoma (T-ALL/LBL): Phase 2 Results

Data Driven Research through the European RADeep Registry and the Use of Artificial Intelligence Towards Personalized Medicine in Sickle Cell Disease

WUC007-03: A Phase 2 Study of Anti-CD7 Allogenic CAR-T Cells (WT-7) in Patients with Relapsed/Refractory (R/R) T-Cell Acute Lymphoblastic Leukemia (T-ALL)/Lymphoblastic Lymphoma (LBL)

Single-Agent Subcutaneous Blinatumomab for Advanced B-Cell Acute Lymphoblastic Leukemia: Long-Term Follow-up from a Phase 1b Dose Expansion Cohort

Mapping Total Cortical Volume of Children and Adolescents with Sickle Cell Disease Against Normative Growth Trajectories: First Baseline Results of the Brick Study

Transcriptional Profiling Directs the Classification of Mixed Phenotype Acute Leukemias into AML, B-ALL or T-ALL

One-Year Safety and Efficacy of Mitapivat in Sickle Cell Disease: Follow-up Results of a Phase 2, Open-Label Study

Novel Insights in TKI Resistance in BCR :: ABL1 -Positive B-Cell Acute Lymphoblastic Leukemia Beyond Kinase Domain Mutations

Use of Race and Ethnicity in Sickle Cell Disease Research

Pyruvate Kinase Thermostability Is Associated with Red Blood Cell Adhesion, Deformability and Oxygen Affinity in Patients with Sickle Cell Disease

Red Blood Cell Pyruvate Kinase Properties in Sickle Cell Disease - of Mice and Men

The HOVON 100 Study in Adult Acute Lymphoblastic Leukemia Re-Analysed By Multi-State Modeling: Benefits and Risks of Clofarabine

Untargeted Metabolomics on Dried Blood Spots of Patients with Sickle Cell Disease Treated with the Pyruvate Kinase Activator Mitapivat

Robust Validation of the UKALL High Hyperdiploid Risk Profile Using Individual Patient Data Collected By the Harmony Alliance

Safety and Efficacy of Mitapivat (AG-348), an Oral Activator of Pyruvate Kinase R, in Subjects with Sickle Cell Disease: A Phase 2, Open-Label Study (ESTIMATE)

Preclinical Development of AT1412, a Patient Derived CD9 Antibody That Does Not Induce Thrombosis for Treatment of B ALL

Real-World Effectiveness and Safety of Blinatumomab in Adults with Relapsed or Refractory B-Cell Precursor Acute Lymphoblastic Leukaemia in Europe: 3-Year Results in Philadelphia Chromosome-Negative Patients and a Subset of Patients with Late First Relapse

AT1412, a Patient-Derived Antibody in Development for the Treatment of CD9 Positive Precursor B-Acute Lymphoblastic Leukemia

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only